Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $28.8152W HIGH $97.97
Volume
40.98 K
Value Traded
7.33 M
Short % Float
9.26%
-2.31%Week
+1.68%1 Month
-4.88%3 Month
-6.04%6 Month
-24.77%5 Year
-49.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
197.65 M
EPS (TTM)
-2.20
P/E Ratio
-
Ent. Value
227.82 M
Total Shares
2.81 M
Float Shares
1.32 M
Insiders
59.73%
Institutions
45.92%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SLGL Catalyst Timeline
Dated clinical, regulatory and corporate events for Sol-Gel Technologies Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sol-Gel Technologies Ltd.
354Total events
16Upcoming
96Tier-1 (high impact)
2017 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Last Patient Last VisitSGT-610Trial
Last patient completed last scheduled study visit in pivotal Phase 3 trial of SGT-610 in Gorlin syndrome
Gorlin syndromesource ↗
▲Trial InitiationPatidegibTrial
Proof-of-concept study in HF-BCC initiated
High-frequency BCC (HF-BCC)source ↗
▲Composition Patent FiledIP / Competition
Provisional patent application filed for intra-cystic injectable HHi for OKC
Odontogenic keratocysts (OKC)source ↗
▲Trial InitiationPatidegibTrial
Study evaluating topical patidegib as neo-adjuvant in BCC surgery initiated
BCC surgery (neo-adjuvant)source ↗
▲Patent GrantedSGT-610IP / Competition
Notice of Allowance for method-of-use patent for topical patidegib (SGT-610) extending IP protection to 2044
Gorlin syndromesource ↗
▲Partnership / LicenseTwyneoApprovedCorporate
Exclusive license agreement with Sun Pharmaceutical Industries Ltd. for commercialization of TWYNEO in India
◆Topline ReadoutSGT-610Clinical Data
Top-line results for SGT-610 expected in Q2 2026
Gorlin Syndromesource ↗
▼Equity OfferingCorporate
Pricing of oversubscribed underwritten offering of 459,112 shares at $72.00 per share for gross proceeds of $33.1 million
●Quarterly UpdateCorporate
Filed annual report on Form 20-F for fiscal year ended December 31, 2025
▼Equity OfferingCorporate
Oversubscribed underwritten offering raising ~$33.1 million gross proceeds
▼Topline ReadoutSGT-210Clinical Data
Unblinding of Phase 1b proof-of-concept study of SGT-210 in Darier disease
Darier diseasesource ↗
▼Program DiscontinuationSGT-210Corporate
Decision not to advance SGT-210 to next stage of development in Darier disease
Darier diseasesource ↗
▲Product LaunchEPSOLAYApprovedPost-Market
EPSOLAY launch in Canada by Searchlight Pharma
inflammatory lesions of rosaceasource ↗
▲Other Regulator MilestoneEPSOLAYApprovedEx-US Regulatory
Health Canada approval of EPSOLAY for rosacea
inflammatory lesions of rosaceasource ↗
▲Enrollment CompleteSGT-610Trial
Completed enrollment in pivotal Phase 3 trial of SGT-610 for Gorlin syndrome
Gorlin syndromesource ↗
▲Enrollment CompleteSGT-610Trial
SGT-610 Phase 3 trial enrollment completion expected no later than Q3 2025
Gorlin syndromesource ↗
◆Reverse Stock SplitCorporate
Nasdaq grants 180-day extension to regain minimum bid price compliance; company may effect reverse stock split
◆Reverse Stock SplitCorporate
Reverse share split at ratio 10-for-1 to regain Nasdaq compliance
▲Partnership / LicenseCorporate
Sol-Gel and Mayne Pharma enter into product purchase agreement for U.S. rights to EPSOLAY and TWYNEO
●IND SubmissionSGT-210IND
Phase 2 IND filing for SGT-210 anticipated in Q2 2025
Darier diseasesource ↗
◆Topline ReadoutSGT-610Clinical Data
Topline results expected from Phase 3 trial of SGT-610 for Gorlin syndrome
Gorlin syndromesource ↗
▲Trial InitiationSGT-610Trial
Phase 3 clinical trial of SGT-610 ongoing with over 40 clinical sites activated
Gorlin Syndromesource ↗
▲Trial InitiationSGT-210Trial
Proof-of-concept study for SGT-210 in Darier disease ongoing
Darier diseasesource ↗
▲Partnership / LicenseTwyneoApprovedCorporate
License agreement for commercialization of Twyneo in South Korea signed on September 27, 2024
acne vulgarissource ↗
▲Partnership / LicenseEPSOLAYApprovedCorporate
License agreement for commercialization of Epsolay in South Korea signed on September 27, 2024
rosaceasource ↗
▲Enrollment MilestoneSGT-610Trial
Over 30 clinical sites activated for Phase 3 trial of SGT-610
Gorlin Syndromesource ↗
▲Partnership / LicenseCorporate
Signed new agreement with Padagis for generic roflumilast cream
▲Partnership / LicenseTwyneoApprovedCorporate
Signed six exclusive license agreements for TWYNEO in Europe and South Africa
acne vulgarissource ↗
▲Partnership / LicenseEPSOLAYApprovedCorporate
Signed six exclusive license agreements for EPSOLAY in Europe and South Africa
inflammatory lesions of rosaceasource ↗
▲Partnership / LicenseTwyneoApprovedCorporate
Six license agreements signed in July 2024 for Twyneo in various territories
acne vulgarissource ↗
▲Partnership / LicenseEPSOLAYApprovedCorporate
Six license agreements signed in July 2024 for Epsolay in various territories
rosaceasource ↗
Past FDA Catalysts and PDUFA Decisions
How SLGL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | SGT-210 (topical erlotinib) | Phase 1b topline data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$11M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 46%
Micro Cap(rank 303 of 658)
Percentile Rank
Sol-Gel Technologies Ltd. faces pipeline headwinds (38/100), with $387M risk-adjusted pipeline value, led by S6G5T-3 in Acne Vulgaris (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| S6G5T-3 Small moleculeCompletedNCT04059523 | Acne Vulgaris | Phase 3 | COMPLETED | 1,646 | Feb 6, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every SLGL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Opaleye Management Inc.10% Owner | Buy | 1,493 540,000 held | $65.95 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SLGL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 5.2 % (108 %) | 39.61 M | 500.00 K | 10.2% ( 46.26 K) |
SLGL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SLGL ranks across every disease it competes in
Competitive Position is a premium feature
See how SLGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSLGL News
SLGLSol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
Sol-Gel Technologies will host a KOL Investor Event on October 14, 2026, in New York to discuss SGT-610, a treatment for Gorlin Syndrome. Esteemed experts will address the significant disease burden and the need for effective therapies. A live webcast will be available for those unable to attend in person.
Read more →SLGLSol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Sol-Gel Technologies has announced the completion of the last patient visit in its pivotal Phase 3 trial of SGT-610 for Gorlin syndrome. The study aims to evaluate the efficacy of SGT-610 in preventing basal cell carcinoma lesions. The company plans to lock the database and conduct statistical analysis, with top-line results expected in late November 2026.
Read more →SLGLSol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel Technologies reported its Q2 2026 financial results, highlighting ongoing advancements in its pivotal Phase 3 trial of SGT-610 for Gorlin syndrome, with top-line results expected in late November 2026. The company has also initiated new studies for high-frequency basal cell carcinoma and filed a provisional patent for an injectable treatment targeting odontogenic keratocysts. Despite a decrease in revenue and a net loss, the company remains focused on its clinical programs and commercialization strategy.
Read more →SLGLSol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel Technologies reported its Q1 2026 financial results, highlighting significant corporate advancements. The company received a Notice of Allowance for a method-of-use patent for SGT-610, extending protection until 2044. Additionally, an oversubscribed offering raised $33.1 million, while the pivotal Phase 3 trial for Gorlin syndrome is on track for results in Q4 2026. Sol-Gel also signed a licensing agreement with Sun Pharma for TWYNEO® in India.
Read more →SLGL▲ +20.9%on this news
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. has announced the pricing of an oversubscribed underwritten offering of 459,112 ordinary shares at $72.00 per share, aiming to raise approximately $33.1 million. The proceeds will support the development of SGT-610, a Phase 3 treatment for Gorlin syndrome, alongside general corporate purposes. The offering is expected to close on March 25, 2026.
Read more →SLGL▲ +8.5%on this newsshared move
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Sol-Gel Technologies, Ltd. has filed its annual report on Form 20-F with the SEC for the fiscal year ending December 31, 2025. This report includes audited financial statements and is available for shareholders and the public online. The company is advancing its investigational drug SGT-610, a topical treatment for preventing basal cell carcinoma lesions, alongside its existing FDA-approved products. The filing underscores Sol-Gel's commitment to transparency and innovation in dermatological treatments.
Read more →SLGLSol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
Sol-Gel Technologies announced that the unblinded data from its Phase 1b study of SGT-210 for Darier disease did not demonstrate efficacy compared to the vehicle control. As a result, the company has decided not to proceed with further development of SGT-210. Instead, Sol-Gel will focus on small feasibility studies in other areas and continue its Phase 3 program for SGT-610 in Gorlin syndrome.
Read more →SLGLSol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Technologies reported its Q3 2025 financial results, highlighting ongoing progress in its late-stage pipeline, particularly the pivotal Phase 3 trial of SGT-610 for Gorlin syndrome. The company noted a significant decrease in total revenue compared to the previous year, alongside a net loss of $5.9 million. However, the approval of EPSOLAY in Canada and new partnerships are expected to enhance revenue streams moving forward.
Read more →SLGL▲ +19.7%on this news
Sol-Gel Announces Health Canada Approval of EPSOLAY®
Sol-Gel Technologies announced that Health Canada has approved EPSOLAY for treating inflammatory lesions of rosacea in adults. This approval follows a partnership with Searchlight Pharma, which will commercialize EPSOLAY in Canada. Sol-Gel stands to gain up to $11 million in milestone payments and royalties, bolstering its financial strategy and growth potential.
Read more →SLGLSol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Technologies reported strong financial results for Q2 2025, with revenues increasing significantly compared to the previous year. The company completed enrollment in its Phase 3 trial for SGT-610, aimed at treating Gorlin syndrome, and anticipates reporting data in late 2026. Despite some recruitment challenges for another product, the company is optimistic about future revenues from both existing products and international markets.
Read more →SLGLSol-Gel Reports First Quarter 2025 Results
Sol-Gel Technologies, Ltd. reported its financial results for Q1 2025, showing a revenue increase to $1 million. However, the company experienced a net loss of $8.8 million, up from $6.3 million in Q1 2024. R&D expenses rose significantly, primarily due to costs associated with manufacturing development for future products. Despite these challenges, Sol-Gel has enough cash to fund operations into 2027.
Read more →SLGLSol-Gel Announces Reverse Share Split
Sol-Gel Technologies Ltd. has announced a 10-for-1 reverse share split to increase its share price and comply with Nasdaq's minimum bid price requirement. Shareholders approved the split during a special meeting, and it will take effect on May 2, 2025. The company aims to maintain its listing on Nasdaq while adjusting its share capital and par value accordingly.
Read more →SLGL▲ +14.6%on this news· ran to +46% by day 3
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Sol-Gel Technologies has entered a product purchase agreement with Mayne Pharma for the U.S. rights to EPSOLAY and TWYNEO, securing $16 million to extend its cash runway. This agreement follows the termination of a prior license with Galderma. Sol-Gel is focusing on advancing its SGT-610 program, which aims to be the first preventative treatment for basal cell carcinomas in Gorlin syndrome patients. The Phase-III trial for SGT-610 is progressing well, with expectations for timely recruitment and results.
Read more →SLGLSol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Sol-Gel Technologies has been granted a 180-day extension by Nasdaq to regain compliance with its minimum bid price requirement. The extension allows the company until May 19, 2025, to meet the necessary criteria. Sol-Gel plans to consider a reverse stock split if needed to achieve compliance. The company has also successfully transferred its listing to the Nasdaq Capital Market.
Read more →SLGLSol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. reported its third quarter 2024 financial results, indicating a net loss of $0.4 million. The company announced the appointment of Mori Arkin as interim CEO, effective January 1, 2025. Sol-Gel is currently conducting a Phase 3 clinical trial of SGT-610 for Gorlin syndrome and has received notable licensing agreements to strengthen its financial position. The company's Ordinary Shares will transfer to the Nasdaq Capital Market as part of compliance measures.
Read more →SLGLSol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. reported strong financial results for Q2 2024, including a net income of $1.9 million, showcasing a significant improvement from a net loss of $6 million in the previous year. The company extended its cash runway into the first quarter of 2026, driven by cost-cutting measures and recent agreements. Key developments include the ongoing Phase 3 clinical trial for SGT-610 aimed at treating Gorlin syndrome, with top-line results expected in Q2 2026, and successful licensing agreements for TWYNEO and EPSOLAY targeting international markets. Additionally, the company announced a management realignment to optimize leadership and direction moving forward.
Read more →SLGL▼ -32.9%on this news
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO and EPSOLAY in Europe and South Africa
Sol-Gel Technologies, Ltd. has signed six exclusive license agreements with multiple partners for the commercialization of its dermatological products, TWYNEO and EPSOLAY, in numerous European countries and South Africa. This move is expected to enhance its market presence and generate up to low 7-digit USD payments in upfront and milestone revenues. CEO Alon Seri-Levy emphasized the new agreements as a testament to Sol-Gel's innovative capacity and expressed optimism for additional partnerships in the future. However, the company acknowledges challenges such as potential delays in regulatory submissions and the significant competition in the dermatology market.
Read more →SLGL▼ -8.1%on this news
Sol-Gel Technologies Announces Management Realignment
Sol-Gel Technologies, Ltd. announced a management realignment, including the planned departure of CEO Dr. Alon Seri-Levy effective December 31, 2024, contingent on shareholder approval. Mr. Eyal Ben-Or, previously the Director of Finance, has been appointed as the new Chief Financial Officer. Dr. Seri-Levy will provide consulting services for one year post-departure. The changes come as Sol-Gel continues its clinical trials for SGT-610, a dermatological treatment for Gorlin syndrome, along with its existing product portfolio.
Read more →SLGLSol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Technologies, Ltd. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement due to its shares trading below $1 for 33 consecutive days. The company has until November 18, 2024, to regain compliance by ensuring the share price meets the requirement for at least ten consecutive trading days. While the notice does not immediately affect its listing, Sol-Gel is actively assessing strategies to resolve this issue and maintain its Nasdaq status. The company continues its efforts in dermatology, including ongoing clinical trials for its product candidates.
Read more →SLGL▼ -6%on this news
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. reported its financial results for Q1 2024 and highlighted key corporate developments. The company is progressing with its Phase 3 clinical trial for SGT-610, aimed at treating Gorlin Syndrome, and has entered into an agreement with Beimei Pharma to commercialize TWYNEO in multiple markets. Despite a small revenue increase compared to the prior year, Sol-Gel reported a net loss of $6.3 million for the quarter, although this reflects improvement from the previous year. The company's cash resources are expected to sustain operations into the second half of 2025.
Read more →About Sol-Gel Technologies Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next SLGL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime